Cooper Firms (NASDAQ:COO – Get Free Report) had its worth goal boosted by analysis analysts at Robert W. Baird from $118.00 to $125.00 in a observe issued to buyers on Thursday, Benzinga studies. The agency presently has an “outperform” score on the medical gadget firm’s inventory. Robert W. Baird’s goal worth suggests a possible upside of 32.22% from the corporate’s earlier shut.
COO has been the subject of plenty of different studies. Wells Fargo & Firm lifted their worth goal on Cooper Firms from $110.00 to $115.00 and gave the inventory an “obese” score in a analysis report on Thursday. Needham & Firm LLC reissued a “maintain” score on shares of Cooper Firms in a analysis observe on Friday, August twenty third. Piper Sandler upped their goal worth on Cooper Firms from $115.00 to $120.00 and gave the inventory an “obese” score in a report on Thursday. Lastly, Jefferies Monetary Group upgraded Cooper Firms from a “maintain” score to a “purchase” score and lifted their worth goal for the corporate from $107.00 to $115.00 in a analysis report on Tuesday, July sixteenth. 4 equities analysis analysts have rated the inventory with a maintain score and ten have assigned a purchase score to the corporate’s inventory. In accordance with information from MarketBeat.com, the inventory presently has a consensus score of “Average Purchase” and a mean worth goal of $113.16.
Get Our Newest Analysis Report on COO
Cooper Firms Worth Efficiency
COO opened at $94.54 on Thursday. The inventory’s 50 day easy transferring common is $90.97 and its 200 day easy transferring common is $94.04. The corporate has a debt-to-equity ratio of 0.34, a present ratio of 1.95 and a fast ratio of 1.14. Cooper Firms has a 1 12 months low of $75.93 and a 1 12 months excessive of $104.07. The agency has a market cap of $18.82 billion, a price-to-earnings ratio of 55.61, a PEG ratio of two.34 and a beta of 0.98.
Cooper Firms (NASDAQ:COO – Get Free Report) final issued its quarterly earnings information on Wednesday, August twenty eighth. The medical gadget firm reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. The agency had income of $1 billion for the quarter, in comparison with analyst estimates of $997.30 million. Cooper Firms had a return on fairness of 8.87% and a internet margin of 9.11%. The enterprise’s quarterly income was up 7.8% in comparison with the identical quarter final 12 months. Throughout the identical interval final 12 months, the corporate earned $0.84 EPS. As a gaggle, analysts predict that Cooper Firms will submit 3.57 earnings per share for the present 12 months.
Institutional Buying and selling of Cooper Firms
Plenty of massive buyers have lately made modifications to their positions within the inventory. Benjamin F. Edwards & Firm Inc. boosted its holdings in shares of Cooper Firms by 248.6% within the first quarter. Benjamin F. Edwards & Firm Inc. now owns 244 shares of the medical gadget firm’s inventory price $25,000 after shopping for a further 174 shares over the past quarter. Innealta Capital LLC purchased a brand new stake in shares of Cooper Firms in the course of the 2nd quarter valued at $25,000. Covestor Ltd elevated its stake in shares of Cooper Firms by 305.9% within the 1st quarter. Covestor Ltd now owns 276 shares of the medical gadget firm’s inventory price $28,000 after buying a further 208 shares within the final quarter. Crewe Advisors LLC lifted its place in Cooper Firms by 286.4% in the course of the second quarter. Crewe Advisors LLC now owns 340 shares of the medical gadget firm’s inventory valued at $30,000 after buying a further 252 shares within the final quarter. Lastly, World Retirement Companions LLC grew its holdings in Cooper Firms by 358.6% in the course of the first quarter. World Retirement Companions LLC now owns 321 shares of the medical gadget firm’s inventory valued at $33,000 after buying a further 251 shares in the course of the interval. 24.39% of the inventory is presently owned by institutional buyers.
Cooper Firms Firm Profile
The Cooper Firms, Inc, along with its subsidiaries, develops, manufactures, and markets contact lens wearers. The corporate operates in two segments, CooperVision and CooperSurgical. The CooperVision phase gives spherical lense, together with lenses that appropriate close to and farsightedness; and toric and multifocal lenses comprising lenses correcting imaginative and prescient challenges, equivalent to astigmatism, presbyopia, and myopia within the Americas, Europe, Center East, Africa, and Asia Pacific.
Beneficial Tales
Obtain Information & Rankings for Cooper Firms Every day – Enter your e mail handle beneath to obtain a concise every day abstract of the newest information and analysts’ rankings for Cooper Firms and associated corporations with MarketBeat.com’s FREE every day e mail e-newsletter.
